KIMS Hospitals Q3 FY26 Earnings Call Transcript Released
KIMS Hospitals released its Q3 FY26 earnings call transcript. The company reported record revenue of ₹1,003 crores, up 2.2% YoY, but EBITDA declined 0.4% YoY to ₹204 crores. New units are stabilizing, with expected real growth from FY27. A new hospital agreement in Chennai was also signed.
The release of an earnings call transcript is a routine disclosure for listed companies. While it provides detailed operational and financial insights, it does not announce a new, significant event that would drastically alter the company's trajectory. The information shared, including revenue growth offset by profitability decline, suggests a moderate impact.
The company reported record revenue but a decline in profitability (EBITDA and PAT) due to new unit stabilization. While there are positive developments like expansion and operational improvements, the mixed financial results lead to a neutral sentiment.
Krishna Institute of Medical Sciences Limited (KIMS) has released the transcript of its Q3 FY26 earnings conference call with investors and analysts, held on February 09, 2026. The call featured insights from key management personnel including Dr. Bhaskar Rao Bollineni (Founder and Managing Director), Dr. Abhinay Bollineni (Executive Director and CEO), and Mr. Sachin Salvi (CFO).
During the call, the management highlighted that Q3 FY26 was a record-breaking quarter in terms of revenue, crossing the ₹1,000 crore mark, with total revenue reported at ₹1,003 crores, a 2.2% year-on-year growth. However, EBITDA saw a marginal decline of 0.4% YoY to ₹204 crores, and PAT decreased to ₹52 crores from ₹93 crores in Q3 FY25. This was attributed to EBITDA erosion from newer units. Consolidated revenue from operations stood at ₹998 crores, a 29.2% YoY growth.
Operational highlights included growth in Average Revenue Per Operating Bed (ARPOB) and Average Revenue Per Patient (ARPP). Significant developments were also discussed, such as an agreement for a new hospital in Chennai on a 26-year lease, successful transplants and cardiac procedures at new units in Bangalore and Thane, and an event for World Cancer Day. The company also noted accomplishments in 2025, including the launch of seven new hospitals and a high volume of transplants and robotic surgeries.
The management expressed optimism that the new units are stabilizing and expected to show real growth from the next financial year. They also provided updates on expansion plans, insurance empanelments, and strategies for different clusters, including targets for occupancy and breakeven points for new facilities.
What to do with a filing like this
Krishna Institute of Medical Sciences Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krishna Institute of Medical Sciences Limited. Read the original for the full detail.